Key takeaways
- Synthetic peptides carry a predictable set of impurities, and the only way to know how much of them a given lot contains is to measure it.
- Testing performed by the manufacturer answers a different question from testing performed by an independent laboratory with no stake in the result.
- A credible third-party report names the laboratory, the method, the instrument class, the acceptance criteria and the lot number, and can be verified with the laboratory directly.
- Independent testing verifies what is in the vial at the time of sampling; it does not certify storage, handling or anything that happens afterwards.
Research peptides occupy an unusual position. They are made by the same chemistry, to the same sequences, as compounds studied in university laboratories and, in some cases, sold as approved drugs. But they are not manufactured under the regulatory oversight that governs pharmaceutical production, and no agency inspects the final product before it ships. In that gap, the only external check on what a vial contains is analytical testing, and the only version of that testing that carries weight is the version done by someone who does not profit from the answer. This note sets out why independent testing matters for synthetic peptides specifically, what a laboratory can and cannot verify, how to judge whether a certificate of analysis is credible, and where the limits of the whole approach lie.
What can go wrong in a synthetic peptide
Solid-phase peptide synthesis builds a chain one residue at a time, and each coupling step has a yield slightly below 100 percent. Over a 29-residue peptide like sermorelin or a 44-residue peptide like tesamorelin, those small inefficiencies compound. The result is a crude product containing the target sequence alongside a population of related impurities: deletion sequences missing one residue, truncated chains that stopped early, sequences with a protecting group left on, oxidized methionine or tryptophan, deamidated asparagine or glutamine, and racemized residues where an L-amino acid has flipped to its D-form during activation.1 Purification by preparative HPLC removes most of these, but the fraction that remains depends on how carefully the purification was run and how closely the impurities resemble the target.
D’Hondt and colleagues, in a comprehensive review of peptide-related impurities, grouped these species into categories and noted that several are difficult to separate chromatographically from the target because they differ by a single residue or a single stereocenter.1 This is the central technical reason testing matters: a peptide can look correct by one method and still carry impurities that only a second method reveals. The regulatory framework for approved synthetic peptides reflects this. The FDA’s 2021 guidance on synthetic versions of recombinant-origin peptide drugs asks applicants to identify any peptide-related impurity present above 0.10 percent and to justify that new impurities do not raise immunogenicity concerns, using orthogonal analytical methods to do so.2 Research-grade material is not subject to that guidance, but the impurity chemistry is identical.
Why “in-house” is not the same as “tested”
Most manufacturers test their own product, and most of that testing is honest. The problem is structural rather than moral. A manufacturer’s laboratory reports to the same management that set the production targets, and its results affect whether a lot is released or reworked at a cost. That is a conflict of interest whether or not anyone acts on it. In pharmaceutical manufacturing this conflict is managed by regulation: quality units are required to be independent of production, and inspectors audit the records. Research peptide suppliers operate without that external audit, so the independence has to come from somewhere else.
An independent laboratory removes the conflict by having no stake in the result. It is paid the same whether the sample passes or fails. It has no knowledge of the production history and no reason to interpret a borderline chromatogram charitably. This is the same logic that underlies financial audits and building inspections: the value of the check comes from the separation between the party doing the work and the party evaluating it. A supplier who publishes independent results is not claiming its own laboratory is untrustworthy; it is accepting that trust in its own laboratory is not something a customer can verify from outside.
A purity figure is only as independent as the laboratory that produced it.
What a third-party laboratory actually measures
An independent report on a research peptide typically covers between two and five attributes, depending on what the client requested. The table below summarizes the common tests, what each establishes and what it leaves open. Each is covered in more detail in its own note in this library.
| Test | Question answered | What it does not tell you |
|---|---|---|
| HPLC purity | What fraction of the UV-absorbing material elutes as the main peak | Whether the main peak is the right compound; how much material is in the vial |
| Mass spectrometry | Whether the main peak has the molecular weight the sequence predicts | Sequence order or stereochemistry, unless MS/MS is performed |
| Net peptide content | What fraction of the vial’s mass is actually peptide, excluding water and counter-ions | Purity of that peptide |
| Endotoxin (LAL or recombinant) | Whether bacterial lipopolysaccharide is present above a threshold | Presence of other contaminants or of viable microorganisms |
| Sterility | Whether viable microorganisms grow from the sample under defined conditions | Endotoxin, which persists after organisms are killed |
Two points follow from the table. First, no single test is sufficient; purity by HPLC and identity by mass spectrometry are the minimum pair, and net content is what connects both to the quantity on the label. Second, the tests are orthogonal, meaning they measure different physical properties, so an impurity that hides from one is likely to be caught by another. Our notes on HPLC, mass spectrometry, net content and endotoxin testing explain each method in turn.
What makes a laboratory credible
Independence alone is not enough; the laboratory also has to be competent, and competence has recognized markers. The most widely used is accreditation to ISO/IEC 17025, the international standard for testing and calibration laboratories. Accreditation means an external body has audited the laboratory’s quality system, staff training, equipment calibration, method validation and record-keeping, and continues to audit them on a schedule.3 It does not guarantee every result is correct, but it means the laboratory has documented procedures and someone outside it has checked that they are followed. Accreditation is also scoped: a laboratory may be accredited for HPLC but not for endotoxin testing, and a credible report will make the scope clear.
Method validation
Underneath accreditation sits method validation, the process of demonstrating that an analytical procedure does what it claims. The international reference is ICH Q2(R2), adopted by the FDA as guidance in 2024, which defines the performance characteristics a method must demonstrate: specificity, accuracy, precision, linearity, range and detection or quantitation limits.4 A laboratory that has validated its HPLC method for a given peptide can state, with evidence, how small an impurity it can detect and how reproducible its purity figure is from run to run. One that has not can only report what the instrument printed. When a COA gives a purity of 99.2 percent, the meaningful question is what the uncertainty on that figure is, and only a validated method can answer it.
Reference standards
Identity and quantity both depend on comparison to a known standard. For pharmaceutical peptides, pharmacopeial reference standards exist with certified purity values. For most research peptides they do not, and laboratories work from well-characterized in-house standards or from first-principles methods such as amino-acid analysis that do not require a reference of the same peptide. Josephs and colleagues reviewed how metrology institutes establish traceable purity values for peptides and emphasized that a purity figure is only meaningful when the method used to generate it is stated alongside.5 The same principle applies to a COA: the number is inseparable from the method.
How to check that a COA is real
A certificate can be forged, edited or reused from a different lot, and readers have a legitimate interest in detecting that. Several features distinguish a verifiable report from a decorative one.
- The laboratory is named and has an independent web presence, contact details and, ideally, a published accreditation certificate with a scope.
- The report carries a unique report number and a sample or lot identifier that matches the vial.
- The method is stated with enough detail to be meaningful: instrument type, column, detection wavelength, and for mass spectrometry the ionization mode and mass convention.
- Acceptance criteria are printed alongside results, so “conforms” has a defined meaning.
- The laboratory will confirm the report on request. Reputable laboratories expect this and treat it as routine.
Wednesday publishes the third-party report for each lot in the COA library, with the laboratory identified so that any reader can verify the document at source. Our guide to reading a certificate of analysis walks through a sample report line by line.
Reading the evidence
The presence of a COA is not itself evidence of quality. A report from an unnamed laboratory, without a lot number, listing purity to two decimal places with no method or tolerance, tells you almost nothing. A report that is verifiable, scoped and specific tells you a great deal about one lot at one moment.
What independent testing cannot do
It is worth being precise about the limits, because overstating them undermines the case. Third-party testing verifies the composition of a sample at the time it was analyzed. It does not verify that every vial in the lot is identical to the sample, although a well-controlled lyophilization process makes lot homogeneity a reasonable assumption. It does not verify the conditions under which the product was shipped or stored afterwards, which is why storage and handling is a separate topic. And it says nothing about biological activity: a peptide can be chemically correct and still have lost function through misfolding or aggregation that standard purity methods do not detect, a problem more relevant to large proteins than to short peptides but not absent.
There is also a broader limit. Testing establishes that a research compound is what it is labeled to be. It does not make the compound suitable for any use other than research, and it does not convert a research-grade material into a pharmaceutical. Where an approved drug exists that shares a sequence with a research peptide, as with tesamorelin and Egrifta, the approved product has been manufactured, tested and released under a regulatory framework that research-grade material has not. The purpose of independent testing is to make the research material’s composition transparent, not to erase that distinction. Our note on what “research use only” means covers the regulatory framing in more depth.
Why it matters for research outcomes
The practical case for independent testing is not about marketing; it is about reproducibility. A research result obtained with a peptide of unknown purity, unknown net content and unverified identity is a result that cannot be reproduced, because the input is not defined. Hoofnagle and colleagues, writing recommendations for peptides used in clinical mass-spectrometry assays, made the point directly: peptide purity and quantity from commercial suppliers vary widely, and assays built without independent characterization of the peptide produce systematically wrong results.6 Their recommendation was that laboratories verify identity and content themselves or require it from the supplier. That standard, applied to any research use of a synthetic peptide, is the standard third-party testing is meant to meet.
Independent testing turns a vial from a claim into a specification. It does not make the material more than it is, but it makes what it is knowable, and in research that is the precondition for everything else.
Frequently asked questions
What does third-party tested mean for peptides?
It means an analytical laboratory that is independent of the manufacturer has tested a sample from the lot and issued a report. The tests usually include HPLC purity and mass-spectrometry identity, sometimes with net peptide content, endotoxin and sterility.
How do I verify a peptide COA is legitimate?
Check that the laboratory is named and has an independent presence, that the report number and lot number are printed and match the product, that methods and acceptance criteria are stated, and then contact the laboratory to confirm the report exists. Reputable laboratories confirm on request.
What is ISO 17025 and why does it matter for peptide testing?
ISO/IEC 17025 is the international standard for the competence of testing laboratories. Accreditation means an external body has audited the laboratory’s methods, equipment, training and records. It is scoped to specific tests, so check that the scope includes the method on the report.
Does a 99% purity result mean the peptide is high quality?
Purity is one attribute. A 99 percent HPLC result says that 99 percent of the UV-absorbing material eluted as one peak. It does not confirm identity, quantity, endotoxin level or sterility. Quality is the combination of several tests, not one number.
Can third-party testing guarantee a peptide is safe?
No. It verifies chemical composition and, where tested, endotoxin and sterility of a sample at one point in time. Research peptides are not approved drugs, and testing does not change that. It makes the material’s composition transparent for research purposes.
References & further reading
- D’Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. doi:10.1016/j.jpba.2014.06.012 / PMID 25044089
- US Food and Drug Administration. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin: Guidance for Industry. May 2021. fda.gov
- International Organization for Standardization. ISO/IEC 17025:2017. General requirements for the competence of testing and calibration laboratories. iso.org/standard/66912.html
- US Food and Drug Administration. Q2(R2) Validation of Analytical Procedures: Guidance for Industry (ICH). March 2024. fda.gov
- Josephs RD, et al. Establishment of measurement traceability for peptide and protein quantification through rigorous purity assessment, a review. Metrologia. 2019;56(4):044006. doi:10.1088/1681-7575/ab27e5
- Hoofnagle AN, Whiteaker JR, Carr SA, et al. Recommendations for the generation, quantification, storage, and handling of peptides used for mass spectrometry-based assays. Clin Chem. 2016;62(1):48-69. doi:10.1373/clinchem.2015.250563 / PMID 26719571